A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Summary

To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD7442 in Healthy Chinese Adults. vs. placebo

Timeline

Start

2021-10-09

Primary completion

2021-11-27

Completion

2023-01-16

Publications

• Li N, Zhang J, Zhang W, Xu Z, Yao X, He A, Liu S, Ge X, Liu J, Li Y, Chen CC, Zhang H. Safety, Tolerability, and Pharmacokinetics of the Long-Acting SARS-CoV-2-Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults. Clin Pharmacol Drug Dev. 2025 Nov;14(11):836-845. doi: 10.1002/cpdd.1583. Epub 2025 Aug 13.

Drugs

Indications